Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Luminex Corporation NxTag CoV Extended Panel Assay

ASPR’s Portfolio of COVID-19 Medical Countermeasures  under EUA

BARDA is supporting Luminex Corporation’s development of the NxTAG CoV Extended Panel to be used in the diagnosis of COVID-19. The test uses RNA to detect the presence of the SARS-COV-2 virus and is intended for use with the company’s IVD MAGPIX molecular diagnostic system. This high-throughput option will add test capacity in the U.S. on equipment currently installed in U.S. healthcare facilities. Test results are available in less than four hours. The test capacity of more than 1,000,000 tests/year on equipment currently installed at U.S. healthcare facilities.

Emergency Use Authorization

On March 27, 2020, FDA issued an Emergency Use Authorization (EUA) to allow Luminex Corporation’s NxTAG CoV Extended Panel to be used to diagnose COVID-19.


  • This page last reviewed: May 21, 2020